For outpatient treatment of pyelonephritis in Canada, which antibiotic is NOT preferred?

Study for the Medical Council of Canada Qualifying Examination (MCCQE) I. Engage with flashcards and multiple-choice questions with detailed feedback. Prepare confidently!

Outpatient treatment for pyelonephritis aims for an antibiotic that reliably treats the usual kidney tract pathogens and penetrates renal tissue, while aligned with current local resistance patterns and safety considerations. Fluoroquinolones like ciprofloxacin are increasingly avoided as first-line in Canada because the common uropathogens show rising resistance to these drugs, which makes empirical therapy less reliable. Safety concerns with fluoroquinolones also temper their use, so they’re not the preferred initial option in this setting. The other choices—cephalexin, amoxicillin-clavulanate, and trimethoprim-sulfamethoxazole—remain suitable when the organism is susceptible and local resistance data support their use, offering effective coverage with generally favorable safety profiles. If local data show high TMP-SMX resistance, or if broad beta-lactam coverage is needed, alternatives can be chosen accordingly.